Analyst Ratings For The Medicines (NASDAQ:MDCO)
Today, Chardan Capital reiterated its Buy rating on The Medicines (NASDAQ:MDCO) with a price target of $85.00.
Some recent analyst ratings include
- 1/24/2018-Chardan Capital Reiterated Rating of Buy.
- 1/24/2018-JPMorgan Chase & Co. initiated coverage with a Overweight rating.
- 1/22/2018-Citigroup Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 10/26/2017-Jefferies Group Reiterated Rating of Buy.
- 10/23/2017-Guggenheim initiated coverage with a Buy rating.
- 8/10/2017-Cowen Reiterated Rating of Buy.
- On 12/15/2017 Clive Meanwell, CEO, sold 136,250 with an average share price of $27.24 per share and the total transaction amounting to $3,711,450.00.
- On 12/8/2017 Fredric N Eshelman, Insider, bought 200,000 with an average share price of $26.56 per share and the total transaction amounting to $5,312,000.00.
- On 11/29/2017 Alexander J Denner, Director, bought 170,000 with an average share price of $30.03 per share and the total transaction amounting to $5,105,100.00.
- On 2/7/2017 William Bernard O’connor, CFO, sold 25,833 with an average share price of $46.20 per share and the total transaction amounting to $1,193,484.60.
- On 12/8/2016 Christopher T Cox, EVP, bought 105,500 with an average share price of $33.20 per share and the total transaction amounting to $3,502,600.00.
- On 12/8/2016 Fredric N Eshelman, Director, bought 621,720 with an average share price of $33.77 per share and the total transaction amounting to $20,995,484.40.
- On 9/21/2016 Clive Meanwell, CEO, sold 8,623 with an average share price of $40.00 per share and the total transaction amounting to $344,920.00.
Recent Trading Activity for The Medicines (NASDAQ:MDCO)
Shares of The Medicines closed the previous trading session at 33.33 up +2.86 9.39% with 31.0 shares trading hands.